Truist Financial Increases Lantheus (NASDAQ:LNTH) Price Target to $98.00

Lantheus (NASDAQ:LNTH) had its target price upped by Truist Financial from $89.00 to $98.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price target would indicate a potential upside of 18.64% from the stock’s previous close.

Several other analysts have also weighed in on LNTH. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Mizuho upped their target price on Lantheus from $85.00 to $95.00 and gave the company an “outperform” rating in a report on Monday. Wall Street Zen raised Lantheus from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 28th. William Blair reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research note on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.86.

Lantheus Price Performance

Lantheus stock traded down $0.14 during trading hours on Wednesday, hitting $82.61. The stock had a trading volume of 78,344 shares, compared to its average volume of 933,494. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of 24.53 and a beta of -0.12. Lantheus has a 1-year low of $47.25 and a 1-year high of $108.91. The stock’s fifty day moving average is $75.24 and its two-hundred day moving average is $65.62.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.Lantheus’s revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

A number of large investors have recently made changes to their positions in LNTH. M&T Bank Corp acquired a new stake in shares of Lantheus during the fourth quarter valued at $370,950,000. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after acquiring an additional 1,950,252 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Lantheus during the third quarter valued at $65,654,000. Norges Bank acquired a new stake in shares of Lantheus during the fourth quarter valued at $76,197,000. Finally, Polaris Capital Management LLC purchased a new position in Lantheus during the third quarter worth about $32,687,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.